Eli Lilly's GLP-1 drug is now the world's best-selling drug. Novo Nordisk is struggling with declining market share. Pfizer is desperately trying to get into the GLP-1 game. 10 stocks we like better ...
As Eli Lilly and Novo Nordisk have been battling it out to gain market share of the growing GLP-1 weight loss market, one demographic has been seen as increasingly important: cash-pay customers. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results